MedTrace Logo

Acceptability, Usability and Preliminary Effectiveness of ChatGPT in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults in Hong Kong

NCT06679647 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-11-07

No results posted yet for this study

Summary

In this project, we will train a ChatGPT to provide real-time answers to questions related to the SIV for older adults in Hong Kong.

This study aims to evaluate the usability, acceptability, and preliminary effectiveness of the ChatGPT among 50 community-living people aged 65 years and above in Hong Kong.

The primary objectives are to evaluate the usability and acceptability (including the extent of usage and subjective experiences of behavioural, cognitive, and affective engagement) of the ChatGPT at the end of the 4-week intervention period (T1).

The secondary objectives are to evaluate the following conditions measured at T1, as compared to those measured at baseline (T0):

1. Self-reported uptake of SIV in the past month.
2. Changes in behavioural intention to receive SIV for the approaching flu season.
3. Changes in knowledge and attitudes related to SIV.

Conditions

  • Behavior Change Interventions

Interventions

BEHAVIORAL

Access to a trained ChatGPT

Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Zixin Wang, PhD · Chinese University of Hong Kong

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-03-31
Completion
2025-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06679647 on ClinicalTrials.gov